Influence of myocardial fibrosis on left ventricular hypertrophy in patients with symptomatic severe aortic stenosis

Cardiology

Volumn 120, Issue 3, 2012, Pages 139-145

  Golia, Giorgio ^a   Milano, Aldo D ^b   Dodonov, Mikhail ^b   Bergamini, Corinna ^a   Faggian, Giuseppe ^b   Tomezzoli, Anna ^c   Vassanelli, Corrado ^a  

^a Laboratorio di Emodinamica   (Italy)

^b Unità Operativa di Cardiochirurgia   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Aortic valve stenosis; Echocardiography; Myocardial fibrosis; Ventricular function

Indexed keywords

AGED; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; CARDIOVASCULAR PARAMETERS; ECHOCARDIOGRAPHY; END SYSTOLIC WALL STRESS; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE DIASTOLIC DIAMETER; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS INDEX; HEART LEFT VENTRICLE SYSTOLIC DIAMETER; HEART LEFT VENTRICLE WALL; HEART MUSCLE FIBROSIS; HEART VENTRICLE SEPTUM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; WALL STRESS;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEMODYNAMICS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MYOCARDIUM; STRESS, PHYSIOLOGICAL;

EID: 83755225694     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000334792     Document Type: Article

References (24)

1. Bonow RO, Carabello BA, Chatterjee K, de Leon ACJ, Faxon DP, Freed MD, et al: 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52:e1-e142.
2. Carabello BA, Paulus WJ: Aortic stenosis. Lancet 2009; 373: 956-966.
3. Grossman W, Jones D, McLaurin LP: Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56-64.
4. Chambers J: The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors. Heart 2006; 92: 420-423.
5. Kupari M, Turto H, Lommi J: Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur Heart J 2005; 26: 1790-1796. (Pubitemid 41222328)
6. Lund O, Flo C, Jensen FT, Emmertsen K Nielsen TT, Rasmussent BS, Hansen OK, Pilegaard HK, Kristensen LH: Left ventricular systolic and diastolic function in aortic stenosis. Prognostic value after valve replacement and underlying mechanisms. Eur Heart J 1997; 18: 1977-1987. (Pubitemid 27526131)
7. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, et al: Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003; 107: 984-991. (Pubitemid 36258721)
8. Serneri GG, Modesti PA, Boddi M, Cecioni I, Paniccia R, Coppo M, et al: Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ Res 1999; 85: 57-67. (Pubitemid 29321042)
9. Weidemann F, Herrmann S, Stork S, Niemann M, Frantz S, Lange V, et al: Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009; 120: 577-584.
10. Milano AD, De Carlo M, Mecozzi G, D'Alfonso A, Scioti G, Nardi C, et al: Clinical outcome in patients with 19-mm and 21-mm St Jude aortic prostheses: comparison at long-term follow-up. Ann Thorac Surg 2002; 73: 37-43. (Pubitemid 34084531)
11. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, St John Sutton M, Stewart WJ: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463. (Pubitemid 41821197)
12. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618. (Pubitemid 8066109)
13. Legget ME: Usefulness of parameters of left ventricular wall stress and systolic function in the evaluation of patients with aortic stenosis. Echocardiography 1999; 16: 701-710. (Pubitemid 29483238)
14. Baandrup U, Olsen EG: Critical analysis of endomyocardial biopsies from patients suspected of having cardiomyopathy. 1. Morphological and morphometric aspects. Br Heart J 1981; 45: 475-486. (Pubitemid 11087004)
15. Lund O, Kristensen LH, Baandrup U, Hansen OK, Nielsen TT, Emmertsen K, et al: Myocardial structure as a determinant of pre-and postoperative ventricular function and long-term prognosis after valve replacement for aortic stenosis. Eur Heart J 1998; 19: 1099-1108. (Pubitemid 28321391)
16. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C: Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-581. (Pubitemid 16092908)
17. Lorell BH, Carabello BA: Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000; 102: 470-479. (Pubitemid 30490688)
18. Carabello BA, Green LH, Grossman W, Cohn LH, Koster JK, Collins JJ Jr: Hemodynamic determinants of prognosis of aortic valve replacement in critical aortic stenosis and advanced congestive heart failure. Circulation 1980; 62: 42-48. (Pubitemid 10083095)
19. Carabello BA, Williams H, Gash AK, Kent R, Belber D, Maurer A, et al: Hemodynamic predictors of outcome in patients undergoing valve replacement. Circulation 1986; 74: 1309-1316. (Pubitemid 17189250)
20. Gunther S, Grossman W: Determinants of ventricular function in pressure-overload hypertrophy in man. Circulation 1979; 59: 679-688. (Pubitemid 9154960)
21. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA: Controversies in ventricular remodelling. Lancet 2006; 367: 356-367. (Pubitemid 43151469)
22. Polyakova V, Hein S, Kostin S, Tibor Z, Schaper J: Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004; 44: 1609-1618. (Pubitemid 39369793)
23. Heymans S, MD, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S: Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressureoverloaded human heart. Circulation 2005; 112: 1136-1144. (Pubitemid 41216120)
24. Hefti MA, Harder BA, Eppenberger HM Schaub MC: Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 1997; 29: 2873-2892. (Pubitemid 27510755)